Evidence map›Paper›PMID 40744985›Full record

ArticleScientific reports2025

Fusion of SARS-CoV-2 neutralizing LCB1 peptide with Bacillus amyloliquefaciens RNase improves antiviral efficacy.

Nikita N Kostin, Tatyana V Bobik, Elena V Konovalova, Milita V Kocharovskaya, Maria A Simonova, Natalia Yu Rushkevich, Yuliana A Mokrushina, George A Skryabin, Roman S Kalinin, Sergey I Kovalchuk and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Nikita N KostinM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Tatyana V BobikM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Elena V KonovalovaM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Milita V KocharovskayaM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Maria A SimonovaM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Natalia Yu RushkevichM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Yuliana A MokrushinaM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
George A SkryabinM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Roman S KalininDepartment of Physiology and Cell Biology, College of Medicine, The Ohio State University, 1645 Neil Avenue, Columbus, OH, 43210, USA.
Sergey I KovalchukM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Rustam H ZiganshinM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Leonid A KaluzhskiyLaboratory of Intermolecular Interactions, Institute of Biomedical Chemistry, 10 Building 8, Pogodinskaya Street, Moscow, Russia, 119121.
Oksana V GnedenkoLaboratory of Intermolecular Interactions, Institute of Biomedical Chemistry, 10 Building 8, Pogodinskaya Street, Moscow, Russia, 119121.
Evgeniy O YablokovLaboratory of Intermolecular Interactions, Institute of Biomedical Chemistry, 10 Building 8, Pogodinskaya Street, Moscow, Russia, 119121.
Alexis S IvanovLaboratory of Intermolecular Interactions, Institute of Biomedical Chemistry, 10 Building 8, Pogodinskaya Street, Moscow, Russia, 119121.
Aleksandr S ChernovM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Vitaly A KazakovM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Oksana N KhokhlovaM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Arkady N MurashevM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Senlian HongState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Elena I ShramovaM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Alexey A SchulgaM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Ekaterina N LyukmanovaM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Mikhail P KirpichnikovM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Ivan V SmirnovM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Alexey A BelogurovM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Yuri P RubtsovM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997.
Alexey V StepanovDepartment of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA. stepanov@scripps.edu.
Hongkai ZhangState Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, 94 Weijin Road, Tianjin, 300071, China.
Alexander G GabibovM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997. gabibov@mx.ibch.ru.
Sergey M DeyevM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya, 16/10, Moscow, Russia, 117997. biomem@mail.ru.

Funding

MSHERF 075-15-2021-1049National Key Research and Development Program of China 2022YFC3400803National Key Research and Development Program of China 2023YFC2308003National Natural Science Foundation of China 22177002National Natural Science Foundation of China 32150027
6 · The paper itself

Abstract

Virus-neutralizing peptides (VNPs) emerged as promising antiviral drug candidates with unprecedented specificity and cost-effectiveness during the recent COVID-19 pandemic. However, limited avidity, lack of effector functions, short circulatory half-life, and restricted administration routes make them inferior compared to neutralizing antibodies. To address these constraints, a potent VNP that targets the SARS-CoV-2 S protein is combined with Barnase, a highly active RNA-cleaving enzyme from Bacillus amyloliquefaciens. The resulting LCB1-Barnase (LCB1-Bn) chimera retains strong binding affinity for the SARS-CoV-2 S protein and demonstrates a fourfold reduction in IC

Indexed as

Antiviral AgentsBacillus amyloliquefaciensCOVID-19 Drug TreatmentRibonucleasesSARS-CoV-2AnimalsAntibodies, NeutralizingBacterial ProteinsCOVID-19FemaleHumansMiceMice, TransgenicPeptidesRecombinant Fusion ProteinsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntiviral AgentsBacillus amyloliquefaciens ribonucleaseBacterial ProteinsPeptidesRecombinant Fusion ProteinsRibonucleasesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antiviral peptideBarnaseHalf-life extensionPharmacokineticsSARS-CoV-2Virus neutralizing peptides (VNPs)

Identifiers

PMID40744985
PMCPMC12313848

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.